Dizal Pharmaceutical's Zegfrovy has taken the EGFR inhibitor class into new territory after hitting the mark in a phase 3 ...
The FDA has scheduled a public meeting to discuss its Commissioner's National Priority Voucher (CNPV) programme, amid ...
Novo Nordisk is facing a massive wave of generic competitors to its injectable formulations of GLP-1 agonist semaglutide, used to treat diabetes and obesity, as a key patent in India is due to expire ...
California biotech Kali Therapeutics has snagged its first major pharma partner, Sanofi, which is committing $180 million in near-term payments for rights to a T-cell engager (TCE) for autoimmune ...
Valneva and Pfizer's three-dose shot targets the outer surface protein A (OspA) of the Borrelia burgdorfii bacteria that causes the disease, and has previously shown in phase 2 trials that it ...
Earendil Labs has raised an impressive $787 million in financing for its AI-powered drug discovery and development platform, which has already attracted some big-ticket deals with pharma group Sanofi.
After a successful appeal, reimbursement authority NICE has said the companies' files will now be sent back to the appraisal ...
After a strong start to the year, the value of biotech financings has tailed off a little, but March has seen a clutch of $50 ...
February was a light month for agency and consultancy news, but a few interesting changes came through. Read on for the ...
As the FDA released its draft guidance, the NIH said it will invest $150 million in human-based research to develop the tools ...
This breakthrough has accelerated peptide drug development across multiple therapeutic areas, including cardiovascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results